NRx Pharmaceuticals, Inc. (NASDAQ: NRXP ) will release earnings for its first quarter before the opening bell on Monday, May 18.
Analysts expect the Wilmington, Delaware-based company to report quarterly loss of 11 cents per share, versus a loss of 34 cents per share in the year-ago period. The consensus estimate for NRx Pharmaceuticals' quarterly revenue is $19.43 million, according to Benzinga Pro .
On May 7, NRx Pharma received clearance from the FDA to initiate clinical trial of NRX-101 vs. placebo in patients with depression and suicidality.
NRx Pharmaceuticals shares gained 8.8% to close at $3.21 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
Considering buying NRXP stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Earnings News Price Target Markets Trading Ideas Expert Ideas Most Accurate Analysts